← Back to Clinical Trials
Recruiting NCT06734065

NCT06734065 Effect of Non-Invasive Lung Fluid Monitoring for Heart Failure Management in Primary Care

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06734065
Status Recruiting
Phase
Sponsor Linkoeping University
Condition Heart Failure
Study Type INTERVENTIONAL
Enrollment 330 participants
Start Date 2025-04-16
Primary Completion 2030-07

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
ReDS-guided heart failure management program

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 330 participants in total. It began in 2025-04-16 with a primary completion date of 2030-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Remote dielectric sensing (ReDS) technology offers a non-invasive method for assessing lung congestion. This randomized controlled trial aims to evaluate the effectiveness and processes of the ReDS-guided heart failure management program in primary care settings for patients with heart failure.

Eligibility Criteria

Inclusion Criteria: * Age ≥ 18 years, there is no upper age limit * Diagnosed with heart failure regardless of left ventricular ejection fraction * Having New York Heart Association (NYHA) Class III/IV irrespective of prior hospitalisation for heart failure, or NYHA II with a history of at least one hospitalisation for heart failure within the previous 12 months * Elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) within 12 months: (a) ≥450 pg/ml for patients under 50 years; (b) ≥900 pg/ml for patients aged 50-75 years; (c) ≥1800 pg/ml for patients over 75 years. Exclusion Criteria: * NYHA I * Life expectancy \<6 months * Physical characteristics that prevented use of the ReDS (body mass index \< 22 or \>39, and height less than 155 cm or higher than 195 cm) * Implantation of a left ventricular assist device or cardiac transplantation.

Contact & Investigator

Central Contact

Naoko Perkiö Kato, PhD

✉ naoko.perkio.kato@liu.se

📞 +46 (0)11-36 31 17

Frequently Asked Questions

Who can join the NCT06734065 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06734065 currently recruiting?

Yes, NCT06734065 is actively recruiting participants. Contact the research team at naoko.perkio.kato@liu.se for enrollment information.

Where is the NCT06734065 trial being conducted?

This trial is being conducted at Flen, Sweden.

Who is sponsoring the NCT06734065 clinical trial?

NCT06734065 is sponsored by Linkoeping University. The trial plans to enroll 330 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology